Aytu BioPharma (AYTU) 10-Q 19 May 15 2015 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Mar. 31, 2015	1-May-15
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q3
Trading Symbol	RSWN
Entity Registrant Name	ROSEWIND CORP
Entity Central Index Key	1385818
Current Fiscal Year End Date	-23
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		173,597,365

Balance_Sheets

Balance Sheets (USD $)	Mar. 31, 2015	Jun. 30, 2014
Current assets
Cash and cash equivalents	$1,491,202	$2,639,650
Accounts receivable	1,036
Inventory	11,233
Prepaid expenses	25,000	521,322
Prepaid research and development-related party (Note 9)	121,983	121,983
Deferred tax asset		31,762
Total current assets	1,650,454	3,314,717
Fixed assets, net (Note 2)	36,591	57,246
In-process research and development	7,500,000	7,500,000
Patents, net	646,472	699,563
Long-term portion of prepaid research and development-related party (Note 9)	365,950	457,438
Deposits	1,998
Total non current assets	8,551,011	8,714,247
Total assets	10,201,465	12,028,964
Current liabilities
Accounts payable	546,346	649,504
Accrued liabilities-related party (Note 9)		150,000
Accrued compensation	98,949
Deferred revenue	85,714	85,714
Payable to Ampio	468,550	861,059
Notes to Ampio	8,000,000	4,300,000
Accrued interest to Ampio	3,329	46,002
Total current liabilities	9,202,888	6,092,279
Long-term deferred revenue	447,321	511,607
Noncurrent deferred tax liability		55,672
Total liabilities	9,650,209	6,659,558
Commitments and contingencies (Note 6)
Stockholders' equity
Common stock	4,465	4,465
Additional paid-in capital	13,156,590	12,406,780
Accumulated deficit	-12,609,799	-7,041,839
Total stockholders' equity	551,256	5,369,406
Total liabilities and stockholders' equity	$10,201,465	$12,028,964

Statements_of_Operations

Statements of Operations (USD $)	3 Months Ended		9 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Income Statement [Abstract]
License revenue	$21,429	$12,500	$64,286	$37,500
Product and service revenue	2,400		15,460
Total revenue	23,829	12,500	79,746	37,500
Expenses
Research and development	694,180	1,237,854	2,418,125	2,640,525
Research and development-related party (Note 9)	47,998	28,585	155,994	71,589
General and administrative	1,087,788	737,027	2,986,597	1,715,001
Total operating expenses	1,829,966	2,003,466	5,560,716	4,427,115
Other expense
Interest expense	-36,052	-11,980	-110,900	-11,662
Total other expense	-36,052	-11,980	-110,900	-11,662
Net loss, before income tax	-1,842,189	-2,002,946	-5,591,870	-4,401,277
Deferred income tax benefit		322,569	23,910	549,158
Net loss	($1,842,189)	($1,680,377)	($5,567,960)	($3,852,119)
Weighted average number of common shares outstanding	44,652,500	44,652,500	44,652,500	34,360,529
Basic and diluted net loss per common share	($0.04)	($0.04)	($0.13)	($0.11)

Statement_of_Stockholders_Equi

Statement of Stockholders' Equity (USD $)	Total	Common Stock [Member]	Additional Paid in Capital [Member]	Accumulated Deficit [Member]
Beginning Balance at Jun. 30, 2014	$5,369,406	$4,465	$12,406,780	($7,041,839)
Beginning Balance, shares at Jun. 30, 2014		44,652,500
Stock-based compensation (unaudited)	749,810		749,810
Stock-based compensation (unaudited), shares		0
Net loss (unaudited)	-5,567,960			-5,567,960
Ending Balance at Mar. 31, 2015	$551,256	$4,465	$13,156,590	($12,609,799)
Ending Balance, shares at Mar. 31, 2015		44,652,500

Statements_of_Cash_Flows

Statements of Cash Flows (USD $)	9 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities:
Net loss	($5,567,960)	($3,852,119)
Stock-based compensation expense	749,810	385,342
Depreciation and amortization	73,746	63,596
Amortization of prepaid research and development-related party (Note 9)	91,488	5,083
Deferred taxes	-23,910	-549,159
Adjustments to reconcile net loss to net cash used in operating activities:
(Increase) decrease in accounts receivable	-1,036	24,000
(Increase) in inventory	-11,233
Decrease (increase) in prepaid expenses	496,322	-348,510
(Increase) in prepaid research and development-related party (Note 9)	-150,000	-315,000
(Decrease) increase in accounts payable	-103,158	582,899
(Decrease) increase in related party payable	-392,509	299,469
(Decrease) in deferred revenue	-64,286	-37,500
Increase in accrued compensation	98,949
(Decrease) increase in accrued interest payable	-42,673	12,033
Net cash used in operating activities	-4,846,450	-3,729,866
Cash flows used in investing activities:
Deposits	-1,998
Net cash used in investing activities	-1,998
Cash flows from financing activities:
Proceeds from convertible note to Ampio	3,700,000	4,300,000
Contribution of Ampio		637,209
Net cash provided by financing activities	3,700,000	4,937,209
Net change in cash and cash equivalents	-1,148,448	1,207,343
Cash and cash equivalents at beginning of period	2,639,650	2,913,701
Cash and cash equivalents at end of period	1,491,202	4,121,044
Non-cash transactions:
Issuance of common stock in exchange for Vyrix acquired assets		6,803,356
Related party-prepaid research and development and accrued liability not paid at March 31, 2014		$300,000

Basis_of_Presentation_and_Busi

Basis of Presentation and Business	9 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Basis of Presentation and Business	Note 1 – Basis of Presentation and Business
	Basis of Presentation
	These unaudited financial statements represent the financial statements of Rosewind Corporation (“Rosewind” or “the Company”). Rosewind purchased Luoxis Diagnostics, Inc. (“Luoxis”) and Vyrix Pharmaceuticals, Inc. (“Vyrix”) on April 16, 2015 in a reverse triangular merger. Thus, the Rosewind financial statements presented in this form 10-Q are actually the combined financials of Luoxis and Vyrix for any periods prior to April 16, 2015. These unaudited financial statements should be read in conjunction with Rosewind’s Form 8-K filed April 22, 2015, which included all disclosures required by generally accepted accounting principles, see Note 10 for further details. In the opinion of management, these unaudited financial statements contain all adjustments necessary to present fairly the financial position of Rosewind and the results of operations and cash flows for the interim periods presented. The results of operations for the period ended March 31, 2015 are not necessarily indicative of expected operating results for the full year. The information presented throughout the document as of and for the period ended March 31, 2015 is unaudited. Rosewind’s activities have not generated significant revenue to date.
	Liquidity Disclosure—Company Discusses Liquidity Issues but Believes Actions It Has Taken Will Enable It to Continue as a Going Concern over the Next Year
	At March 31, 2015, Rosewind had cash and cash equivalents of $1,491,000, a working capital deficit of $7,522,000 and an accumulated deficit of $12,610,000. Additionally, we have not generated any material revenue to date and are not profitable, and have incurred losses in each year since our inception.
	Management has taken several actions to ensure that the Company will continue as a going concern through June 30, 2016, including, obtaining a $4.0 million cash infusion from Ampio Pharmaceuticals, Inc. (“Ampio”) during April of 2015 and an additional $10 million commitment from Ampio which will be funded prior to April 15, 2016. As of April 16, 2015, the funding from Ampio was converted into equity of the Company. We intend to seek additional capital within the next 12 months to expand our clinical development activities for Zertane and RedoxSYS. In addition, we intend to evaluate the capital markets from time to time to determine when to raise additional capital in the form of equity, convertible debt or otherwise, depending on market conditions relative to our need for funds at such time, and we will seek to raise additional capital during the next 12 months, if at all, at such time as we conclude that such capital is available on terms that we consider to be in the best interests of us and our stockholders. Lastly, we have entered into numerous distribution agreements and we expect to generate revenue during 2015 and 2016 from sales of our RedoxSYS system. Management believes that these actions will enable Rosewind to continue as a going concern through June 30, 2016.
	Newly Issued Accounting Pronouncements
	In January 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2015-01, “Extraordinary and Unusual Items (Subtopic 225-20): Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items.” The purpose of this amendment is to eliminate the concept of extraordinary items. As a result, an entity will no longer be required to separately classify, present and disclose extraordinary events and transactions. The amendment is effective for annual reporting periods beginning after December 15, 2015 and subsequent interim periods with early application permitted. Management is currently assessing the impact the adoption of ASU 2015-01 will have on our financial statements.
	In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). ASU 2014-15 is intended to define management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern and to provide related footnote disclosures. The amendments in this ASU are effective for reporting periods beginning after December 15, 2016, with early adoption permitted. Management is currently assessing the impact the adoption of ASU 2014-15 will have on our financial statements.
	In May 2014, the FASB issued ASU 2014-09 regarding ASC Topic 606, “Revenue from Contracts with Customers”. The standard provides principles for recognizing revenue for the transfer of promised goods or services to customers with the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance will be effective for annual reporting periods beginning after December 15, 2016. Early adoption is not permitted. We are currently evaluating the accounting, transition and disclosure requirements of the standard and cannot currently estimate the financial statement impact of adoption.
	Business
	Rosewind is a specialty healthcare company concentrating on developing and commercializing products for redox-modulated conditions with an initial focus on urological indications and related conditions. The Company is focused primarily on the urological disorders market, specifically sexual dysfunction and male infertility, and expects to seek expansion opportunities in other urological indications such as urological cancers. The Company maintains a focus on the RedoxSYS oxidation-reduction potential (“ORP”) system as we are focused on commercializing the RedoxSYS system into the global research market while developing numerous clinical applications for this potential first-in-class diagnostic device.

Fixed_Assets

Fixed Assets	9 Months Ended
	Mar. 31, 2015
Property, Plant and Equipment [Abstract]
Fixed Assets	Note 2 – Fixed Assets
	Fixed assets are recorded at cost and, once placed in service, are depreciated on the straight-line method over the estimated useful lives. Fixed assets consist of the following:
		Estimated Useful	As of			As of
		Lives in years	March 31, 2015			June 30, 2014
	Lab equipment	3 - 5	$	90,000		$	90,000
	Less accumulated depreciation			(53,000	)		(33,000	)
	Fixed assets, net		$	37,000		$	57,000

InProcess_Research_and_Develop

In-Process Research and Development	9 Months Ended
	Mar. 31, 2015
Research and Development [Abstract]
In-Process Research and Development	Note 3 – In-Process Research and Development
	In-process research and development (“IPRD”) relates to the Zertane product candidate. The $7,500,000 recorded was based on an independent, third party appraisal of the fair value of the assets acquired. IPRD is considered an indefinite-lived intangible asset and its fair value will be assessed annually and written down if impaired. If the Zertane product candidate obtains regulatory approval and commercial production begins, IPRD will be reclassified to an intangible that will be amortized over its estimated useful life. If the Company decides to abandon the Zertane product, the IPRD would be expensed.

Patents

Patents	9 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	Note 4 – Patents
	Costs of establishing patents, consisting of legal and filing fees paid to third parties, are expensed as incurred. The fair value of the Zertane patents, determined by an independent, third party appraisal to be $500,000 is being amortized over the remaining U.S. patent lives of approximately 11 years. The cost of the ORP related patents was $380,000 when they were acquired and is being amortized over the remaining U.S. patent lives of approximately 15 years. Patents consist of the following:
		As of			As of
		March 31, 2015			June 30, 2014
	Patents	$	880,000		$	880,000
	Less accumulated amortization		(234,000	)		(180,000	)
	Patents, net	$	646,000		$	700,000

License_AgreementRevenue_Recog

License Agreement/Revenue Recognition	9 Months Ended
	Mar. 31, 2015
Text Block [Abstract]
License Agreement/Revenue Recognition	Note 5 – License Agreement/Revenue Recognition
	We have not generated material revenue in our operating history. The license revenue recognized in the 2015 periods and 2014 periods, respectively, represents the amortization of the upfront payments received on our license agreements. The initial payment of $500,000 from the license agreement of Zertane with a Korean pharmaceutical company was deferred and is being recognized over ten years. The initial payment of $250,000 from the license agreement of Zertane with a Canadian-based supplier was deferred and is being recognized over seven years.

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 6 – Commitments and Contingencies
	Commitments and contingencies are described below and summarized by the following table:
		Total		2015		2016		2017		2018		2019		Therafter
	Manufacturing	$	68,000	$	68,000	$	—	$	—	$	—	$	—	$	—
	Clinical research and trial obligations		388,000		388,000		—		—		—		—		—
	Sponsored research agreement with related party		298,000		18,000		70,000		70,000		70,000		70,000		—
	Management fee		1,122,000		66,000		264,000		264,000		264,000		264,000		—
		$	1,876,000	$	540,000	$	334,000	$	334,000	$	334,000	$	334,000	$	—
	Manufacturing
	Rosewind entered into an agreement with a local manufacturing company to build their RedoxSYS system, the current remaining commitment is $68,000.
	Clinical Research and Trial Obligations
	In connection with upcoming clinical trials, Rosewind has a remaining commitment of $189,000 on contracts related to the Zertane drug and has entered into research agreements with a remaining commitment of $199,000 related to the RedoxSYS system.
	Sponsored Research Agreement with Related Party
	Rosewind entered into a Sponsored Research Agreement with TRLLC, a related party, in June 2013. Under the terms of the Sponsored Research Agreement, TRLLC agreed to work collaboratively in advancing the ORP diagnostic platform through research and development efforts. The Sponsored Research Agreement may be terminated without cause by either party on 30 days’ notice (see Note 9—Related Party Transactions).
	Management Fee
	In January 2014 and January 2013, Rosewind entered into agreements with Ampio whereby Rosewind agreed to pay Ampio $22,000 per month for shared overhead which includes costs related to the shared facility, corporate staff, and other miscellaneous overhead expenses. These agreements will be in effect until they are terminated in writing by both parties.

Common_Stock

Common Stock	9 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Common Stock	Note 7 – Common Stock
	Capital Stock
	At March 31, 2015 and June 30, 2014, Rosewind had 120 million shares of common stock authorized with a par value of $0.0001 per share and 20 million shares of preferred stock authorized with a par value of $0.0001 per share.
	Private Placement
	In 2013, the Company completed a private placement. A total of 4,652,500 shares of common stock were issued at $1.00 per share resulting in $4,653,000 of gross proceeds. Net proceeds were $3,980,000 after placement agent and legal fees. The placement agent also received 465,250 warrants to purchase common stock valued at $313,000 in connection with the closing.

Equity_Instruments

Equity Instruments	9 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Equity Instruments	Note 8 – Equity Instruments
	Rosewind has two approved stock option plans (Luoxis 2013 Stock Option Plan and Vyrix 2013 Stock Option Plan) which we have reserved a total of 10.0 million shares of common stock.
	Pursuant to the Luoxis 2013 Stock Option Plan, 5.0 million shares of its common stock were reserved for issuance. Stock option activity is as follows:
		Number of		Weighted			Weighted Average		Aggregate Fair
		Options		Average			Remaining		Value
				Exercise Price			Contractual Life
	Outstanding June 30, 2014		1,950,000	$	1			9.01	$	1,374,000
	Granted		885,000	$	1.6
	Exercised		—	$	—
	Forfeited/Cancelled		—	$	—
	Outstanding March 31, 2015		2,835,000	$	1.19			8.61	$	2,541,000
	Exercisable at March 31, 2015		937,500	$	1			8.26	$	687,000
	Available for grant at March 31, 2015		2,165,000
	Pursuant to the Vyrix 2013 Stock Option Plan, 5.0 million shares of its common stock were reserved for issuance. Stock option activity is as follows:
		Number of		Weighted			Weighted Average		Aggregate Fair
		Options		Average			Remaining		Value
				Exercise Price			Contractual Life
	Outstanding June 30, 2014		950,000	$	0.7			9.54	$	417,000
	Granted		—	$	—
	Exercised		—	$	—
	Forfeited/Cancelled		—	$	—
	Outstanding March 31, 2015		950,000	$	0.7			8.79	$	417,000
	Exercisable at March 31, 2015		475,000	$	0.7			8.79	$	208,000
	Available for grant at March 31, 2015		4,050,000
	Stock-based compensation expense related to the fair value of stock options was included in the statements of operations as research and development expenses and general and administrative expenses as set forth in the table below. Rosewind determined the fair value as of the date of grant using the Black-Scholes option pricing model and expenses the fair value ratably over the vesting period. The following table summarizes stock-based compensation expense for the three and nine months ended March 31, 2015 and 2014:
		Three Months Ended March 31,					Nine Months Ended March 31,
		2015		2014			2015		2014
	Research and development expenses
	Stock options
	Luoxis option plan	$	107,000	$	52,000		$	297,000	$	155,000
	Vyrix option plan		8,000		29,000			26,000		29,000
	General and administrative expenses
	Stock options
	Luoxis option plan		138,000		58,000			371,000		116,000
	Vyrix option plan		19,000		(55,000	)		56,000		85,000
		$	272,000	$	84,000		$	750,000	$	385,000
	Unrecognized expense at March 31, 2015
	Luoxis option plan	$	1,129,000
	Vyrix option plan	$	194,000
	Weighted average remaining years to vest
	Luoxis option plan		2.23
	Vyrix option plan		1.79
	Warrants
	Rosewind issued warrants in conjunction with the closing of its 2013 private placement. A summary of all warrants is as follows:
		Number of		Weighted			Weighted Average
		Warrants		Average			Remaining
				Exercise Price			Contractual Life
	Outstanding June 30, 2014		465,250	$	1			3.92
	Warrants exercised - Private/Registered Direct Placements		—
	Outstanding March 31, 2015		465,250	$	1			3.17
	These warrants were valued using the Black-Scholes option pricing model. In order to calculate the fair value of the warrants, certain assumptions were made regarding components of the model, including the closing price of the underlying common stock, risk-free interest rate, volatility, expected dividend yield, and expected life. Changes to the assumptions could cause significant adjustments to valuation. The Company estimated a volatility factor utilizing a weighted average of comparable published volatilities of peer companies. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for treasury securities of similar maturity. The offering costs and the additional paid-in capital for the warrants associated with the common stock offering was valued at $313,000 using the Black-Scholes valuation methodology.

Related_Party_Transactions

Related Party Transactions	9 Months Ended
	Mar. 31, 2015
Related Party Transactions [Abstract]
Related Party Transactions	Note 9 – Related Party Transactions
	Sales and Purchases of Securities
	In November 2013, pursuant to a subscription agreement, Ampio purchased 20 million shares of Rosewind common stock at a purchase price of $0.0001 per share plus the transfer of certain intellectual property described below.
	Ampio Loan Agreements
	In November 2013 and March 2014, Rosewind entered into loan agreements with Ampio. Pursuant to the loan agreements, which were amended in 2015, Ampio agreed to lend Rosewind up to an aggregate amount of $12 million. Unpaid principal amounts under the loan agreement bear simple interest at the “Applicable Federal Rate” for long-term obligations prescribed under Section 1274(d) of the Internal Revenue Code of 1986, as amended (or any successor provision with similar applicability). The initial term of this loan agreement was for one year, subject to automatic extension of successive one-year terms. Rosewind may repay any outstanding balance at any time without penalty. Ampio has an option of converting any balance outstanding under the loan agreement into shares of Rosewind common stock at the fair market value per share of Rosewind common stock. See Note 10 for further details. As of March 31, 2015 the amount advanced was $8 million with interest rates from 2.17% - 3.32%.
	Assignment and Assumption Agreement
	In December 2013, Rosewind entered into an assignment and assumption agreement with Ampio. Pursuant to the assignment and assumption agreement, Ampio assigned to Rosewind all its rights under a certain manufacturing and supply agreement, license agreement, distribution agreement, services agreement and other agreements related to Rosewind’s product candidates in exchange for 20 million shares of Rosewind stock. Ampio is the majority owner of Rosewind.
	Transfer of Intellectual Property
	In January 2013, Ampio transferred to Rosewind certain intellectual property, including registered and unregistered patents, related to the ORP technology.
	In December 2013, Ampio transferred to Rosewind certain intellectual property, including registered and unregistered patents, related to Zertane product candidates in exchange for stock as described above in the assignment and assumptions agreement.
	Services Agreement
	The Company has service agreements with Ampio which are described in Note 6.
	Sponsored Research Agreement
	In June 2013, Rosewind entered into a sponsored research agreement with TRLLC, an entity controlled by Ampio’s director and Chief Scientific Officer, Dr. Bar-Or. The agreement, which was amended in January 2015 and provides for Rosewind to pay $6,000 per month to TRLLC in consideration for services related to research and development of the Oxidation Reduction Potential platform. In March 2014, Rosewind also agreed to pay a sum of $615,000 which is being amortized over the contractual term of 60.5 months and is divided between current and long-term on the balance sheet; this amount has been paid in full. This agreement is set to expire March 2019 and cannot be terminated prior to March 2017.

Subsequent_Events

Subsequent Events	9 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	Note 10 – Subsequent Events
	From April 1, 2015 through May 19, 2015, the Company received $4.0 million in equity from Ampio.
	On April 16, 2015, Luoxis and Vyrix, each previously a subsidiary of Ampio, entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among Rosewind Corporation, a Colorado corporation and public company (“Rosewind”), Luoxis, Vyrix, two major stockholders of Rosewind and two subsidiaries of Rosewind created solely for the purposes of the Merger (as defined below), and which did not survive the Merger.
	In the first stage of the transaction, each of Luoxis and Vyrix merged with and into one of Rosewind’s merger subsidiaries. Luoxis and Vyrix survived these mergers. The outstanding shares of stock of Luoxis and the outstanding shares of stock of Vyrix were converted into the right to receive shares of common stock in Rosewind. The Luoxis stock and the Vyrix stock were each converted at an exchange factor. The exchange factor for each of them was determined upon the basis of a relative independent value opinion obtained by Ampio prior to the Merger. The outstanding shares of Rosewind’s merger subsidiary that merged with Luoxis were converted into shares of Luoxis as the surviving corporation. The outstanding shares of Rosewind’s merger subsidiary that merged with Vyrix were converted into shares of Vyrix as the surviving corporation. After completion of the first stage of the transaction, Luoxis and Vyrix were wholly-owned subsidiaries of Rosewind.
	In the second stage of the transaction, which occurred on the same day as the first stage of the transaction, each of Luoxis and Vyrix was merged with and into Rosewind, with Rosewind surviving. The first and second stage mergers are referred to collectively as the Merger. Following the consummation of the Merger, Ampio became the holder of 81.5% of the common stock of Rosewind. Accordingly, the combined business of Luoxis and Vyrix was deemed to be the accounting acquirer and these financial statements reflect the historical results of those businesses.
	Included in Ampio’s ownership is 57,970,000 shares of common stock of Rosewind for (i) issuance to Rosewind of a promissory note from Ampio in the principal amount of $10,000,000, maturing on the first anniversary of the Merger; (ii) cancellation of indebtedness of Luoxis to Ampio in the amount of $8,000,000; and (iii) cancellation of indebtedness of Vyrix to Ampio in the amount of $4,000,000.
	As of April 16, the 44,652,500 of outstanding shares of common stock were converted to Rosewind common stock totaling 96,191,193. Prior to the merger, the Rosewind shareholders held 19,435,402 shares of common stock. As a result of the merger, Rosewind’s outstanding shares of common stock is 173,597,365. On June 1, 2015, the Rosewind shareholders will vote on a reverse stock split of the Company’s common stock at a ratio of one new share for every 12.174 shares outstanding.
	Pursuant to the Merger, the outstanding options in the Luoxis and Vyrix 2013 Option Plans were accelerated and cancelled with the Merger. Option holders received either a cash payment per option share equal to the difference between the consideration payable per share of common stock pursuant to the Merger and the exercise price of the option or, if the consideration paid to holders of common stock was less than the exercise price of such options, no amount was paid to the option holder in connection with the cancellation.

Basis_of_Presentation_and_Busi1

Basis of Presentation and Business (Policies)	9 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation
	These unaudited financial statements represent the financial statements of Rosewind Corporation (“Rosewind” or “the Company”). Rosewind purchased Luoxis Diagnostics, Inc. (“Luoxis”) and Vyrix Pharmaceuticals, Inc. (“Vyrix”) on April 16, 2015 in a reverse triangular merger. Thus, the Rosewind financial statements presented in this form 10-Q are actually the combined financials of Luoxis and Vyrix for any periods prior to April 16, 2015. These unaudited financial statements should be read in conjunction with Rosewind’s Form 8-K filed April 22, 2015, which included all disclosures required by generally accepted accounting principles, see Note 10 for further details. In the opinion of management, these unaudited financial statements contain all adjustments necessary to present fairly the financial position of Rosewind and the results of operations and cash flows for the interim periods presented. The results of operations for the period ended March 31, 2015 are not necessarily indicative of expected operating results for the full year. The information presented throughout the document as of and for the period ended March 31, 2015 is unaudited. Rosewind’s activities have not generated significant revenue to date.
Liquidity Disclosure-Company Discusses Liquidity Issues but Believes Actions It Has Taken Will Enable It to Continue as a Going Concern over the Next Year	Liquidity Disclosure—Company Discusses Liquidity Issues but Believes Actions It Has Taken Will Enable It to Continue as a Going Concern over the Next Year
	At March 31, 2015, Rosewind had cash and cash equivalents of $1,491,000, a working capital deficit of $7,522,000 and an accumulated deficit of $12,610,000. Additionally, we have not generated any material revenue to date and are not profitable, and have incurred losses in each year since our inception.
	Management has taken several actions to ensure that the Company will continue as a going concern through June 30, 2016, including, obtaining a $4.0 million cash infusion from Ampio Pharmaceuticals, Inc. (“Ampio”) during April of 2015 and an additional $10 million commitment from Ampio which will be funded prior to April 15, 2016. As of April 16, 2015, the funding from Ampio was converted into equity of the Company. We intend to seek additional capital within the next 12 months to expand our clinical development activities for Zertane and RedoxSYS. In addition, we intend to evaluate the capital markets from time to time to determine when to raise additional capital in the form of equity, convertible debt or otherwise, depending on market conditions relative to our need for funds at such time, and we will seek to raise additional capital during the next 12 months, if at all, at such time as we conclude that such capital is available on terms that we consider to be in the best interests of us and our stockholders. Lastly, we have entered into numerous distribution agreements and we expect to generate revenue during 2015 and 2016 from sales of our RedoxSYS system. Management believes that these actions will enable Rosewind to continue as a going concern through June 30, 2016.
Newly Issued Accounting Pronouncements	Newly Issued Accounting Pronouncements
	In January 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2015-01, “Extraordinary and Unusual Items (Subtopic 225-20): Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items.” The purpose of this amendment is to eliminate the concept of extraordinary items. As a result, an entity will no longer be required to separately classify, present and disclose extraordinary events and transactions. The amendment is effective for annual reporting periods beginning after December 15, 2015 and subsequent interim periods with early application permitted. Management is currently assessing the impact the adoption of ASU 2015-01 will have on our financial statements.
	In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). ASU 2014-15 is intended to define management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern and to provide related footnote disclosures. The amendments in this ASU are effective for reporting periods beginning after December 15, 2016, with early adoption permitted. Management is currently assessing the impact the adoption of ASU 2014-15 will have on our financial statements.
	In May 2014, the FASB issued ASU 2014-09 regarding ASC Topic 606, “Revenue from Contracts with Customers”. The standard provides principles for recognizing revenue for the transfer of promised goods or services to customers with the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance will be effective for annual reporting periods beginning after December 15, 2016. Early adoption is not permitted. We are currently evaluating the accounting, transition and disclosure requirements of the standard and cannot currently estimate the financial statement impact of adoption.
Business	Business
	Rosewind is a specialty healthcare company concentrating on developing and commercializing products for redox-modulated conditions with an initial focus on urological indications and related conditions. The Company is focused primarily on the urological disorders market, specifically sexual dysfunction and male infertility, and expects to seek expansion opportunities in other urological indications such as urological cancers. The Company maintains a focus on the RedoxSYS oxidation-reduction potential (“ORP”) system as we are focused on commercializing the RedoxSYS system into the global research market while developing numerous clinical applications for this potential first-in-class diagnostic device.

Fixed_Assets_Tables

Fixed Assets (Tables)	9 Months Ended
	Mar. 31, 2015
Property, Plant and Equipment [Abstract]
Schedule of Fixed Assets	Fixed assets consist of the following:
		Estimated Useful	As of			As of
		Lives in years	March 31, 2015			June 30, 2014
	Lab equipment	3 - 5	$	90,000		$	90,000
	Less accumulated depreciation			(53,000	)		(33,000	)
	Fixed assets, net		$	37,000		$	57,000

Patents_Tables

Patents (Tables)	9 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Patents	Patents consist of the following:
		As of			As of
		March 31, 2015			June 30, 2014
	Patents	$	880,000		$	880,000
	Less accumulated amortization		(234,000	)		(180,000	)
	Patents, net	$	646,000		$	700,000

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	9 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Summary of Commitments and Contingencies	Commitments and contingencies are described below and summarized by the following table:
		Total		2015		2016		2017		2018		2019		Therafter
	Manufacturing	$	68,000	$	68,000	$	—	$	—	$	—	$	—	$	—
	Clinical research and trial obligations		388,000		388,000		—		—		—		—		—
	Sponsored research agreement with related party		298,000		18,000		70,000		70,000		70,000		70,000		—
	Management fee		1,122,000		66,000		264,000		264,000		264,000		264,000		—
		$	1,876,000	$	540,000	$	334,000	$	334,000	$	334,000	$	334,000	$	—

Equity_Instruments_Tables

Equity Instruments (Tables)	9 Months Ended
	Mar. 31, 2015
Summary of Stock-Based Compensation Expense	The following table summarizes stock-based compensation expense for the three and nine months ended March 31, 2015 and 2014:
		Three Months Ended March 31,					Nine Months Ended March 31,
		2015		2014			2015		2014
	Research and development expenses
	Stock options
	Luoxis option plan	$	107,000	$	52,000		$	297,000	$	155,000
	Vyrix option plan		8,000		29,000			26,000		29,000
	General and administrative expenses
	Stock options
	Luoxis option plan		138,000		58,000			371,000		116,000
	Vyrix option plan		19,000		(55,000	)		56,000		85,000
		$	272,000	$	84,000		$	750,000	$	385,000
	Unrecognized expense at March 31, 2015
	Luoxis option plan	$	1,129,000
	Vyrix option plan	$	194,000
	Weighted average remaining years to vest
	Luoxis option plan		2.23
	Vyrix option plan		1.79
Warrants Issued in Conjunction with its Senior Convertible Debentures	Rosewind issued warrants in conjunction with the closing of its 2013 private placement. A summary of all warrants is as follows:
		Number of		Weighted			Weighted Average
		Warrants		Average			Remaining
				Exercise Price			Contractual Life
	Outstanding June 30, 2014		465,250	$	1			3.92
	Warrants exercised - Private/Registered Direct Placements		—
	Outstanding March 31, 2015		465,250	$	1			3.17
Luoxis Diagnostics [Member]
Stock Option Activity	Pursuant to the Luoxis 2013 Stock Option Plan, 5.0 million shares of its common stock were reserved for issuance. Stock option activity is as follows:
		Number of		Weighted			Weighted Average		Aggregate Fair
		Options		Average			Remaining		Value
				Exercise Price			Contractual Life
	Outstanding June 30, 2014		1,950,000	$	1			9.01	$	1,374,000
	Granted		885,000	$	1.6
	Exercised		—	$	—
	Forfeited/Cancelled		—	$	—
	Outstanding March 31, 2015		2,835,000	$	1.19			8.61	$	2,541,000
	Exercisable at March 31, 2015		937,500	$	1			8.26	$	687,000
	Available for grant at March 31, 2015		2,165,000
Vyrix Pharmaceuticals [Member]
Stock Option Activity	Pursuant to the Vyrix 2013 Stock Option Plan, 5.0 million shares of its common stock were reserved for issuance. Stock option activity is as follows:
		Number of		Weighted			Weighted Average		Aggregate Fair
		Options		Average			Remaining		Value
				Exercise Price			Contractual Life
	Outstanding June 30, 2014		950,000	$	0.7			9.54	$	417,000
	Granted		—	$	—
	Exercised		—	$	—
	Forfeited/Cancelled		—	$	—
	Outstanding March 31, 2015		950,000	$	0.7			8.79	$	417,000
	Exercisable at March 31, 2015		475,000	$	0.7			8.79	$	208,000
	Available for grant at March 31, 2015		4,050,000

Basis_of_Presentation_and_Busi2

Basis of Presentation and Business - Additional Information (Detail) (USD $)	0 Months Ended	1 Months Ended
	Apr. 15, 2016	Apr. 30, 2015	Mar. 31, 2015	Jun. 30, 2014	Mar. 31, 2014	Jun. 30, 2013
Business Acquisition [Line Items]
Cash and cash equivalents			$1,491,202	$2,639,650	$4,121,044	$2,913,701
Accumulated deficit			-12,609,799	-7,041,839
Liquidity [Member]
Business Acquisition [Line Items]
Cash and cash equivalents			1,491,000
Working capital deficit			7,522,000
Accumulated deficit			-12,610,000
Liquidity [Member] | Scenario, Forecast [Member]
Business Acquisition [Line Items]
Cash infusion receivable from Ampio	10,000,000
Liquidity [Member] | Subsequent Event [Member]
Business Acquisition [Line Items]
Cash infusion received from Ampio		$4,000,000

Fixed_Assets_Schedule_of_Fixed

Fixed Assets - Schedule of Fixed Assets (Detail) (USD $)	9 Months Ended
	Mar. 31, 2015	Jun. 30, 2014
Property, Plant and Equipment [Line Items]
Fixed assets, net	36,591	$57,246
Lab Equipment [Member]
Property, Plant and Equipment [Line Items]
Fixed assets, gross	90,000	90,000
Less accumulated depreciation	-53,000	-33,000
Fixed assets, net	37,000	$57,000
Lab Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	3 years
Lab Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years

InProcess_Research_and_Develop1

In-Process Research and Development - Additional Information (Detail) (USD $)	Mar. 31, 2015	Jun. 30, 2014
Indefinite-lived Intangible Assets [Line Items]
In-process research and development	$7,500,000	$7,500,000
Zertane Patents [Member]
Indefinite-lived Intangible Assets [Line Items]
In-process research and development	$7,500,000

Patents_Additional_Information

Patents - Additional Information (Detail) (USD $)	9 Months Ended
	Mar. 31, 2015
Zertane Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Costs of establishing patents	$500,000
Remaining amortization period	11 years
ORP [Member]
Finite-Lived Intangible Assets [Line Items]
Costs of establishing patents	$380,000
Remaining amortization period	15 years

Patents_Schedule_of_Patents_De

Patents - Schedule of Patents (Detail) (USD $)	Mar. 31, 2015	Jun. 30, 2014
Indefinite-lived Intangible Assets [Line Items]
Patents, net	$646,472	$699,563
Patents [Member]
Indefinite-lived Intangible Assets [Line Items]
Patents	880,000	880,000
Less accumulated amortization	-234,000	-180,000
Patents, net	$646,000	$700,000

License_AgreementRevenue_Recog1

License Agreement/Revenue Recognition - Additional Information (Detail) (USD $)	1 Months Ended		3 Months Ended
	Jan. 31, 2014	Jan. 31, 2013	Mar. 31, 2015	Mar. 31, 2014
Revenue Recognition [Line Items]
Amount paid by supplier	$22,000	$22,000
Korean Pharmaceutical Company [Member] | KOREA
Revenue Recognition [Line Items]
Amount paid by supplier			500,000	500,000
Deferred revenue recognition period			10 years	10 years
Canadian-based Supplier [Member] | CANADA
Revenue Recognition [Line Items]
Deferred revenue recognition period			7 years	7 years
Milestone payments earned and recognized			$250,000	$250,000

Commitments_and_Contingencies_1

Commitments and Contingencies - Summary of Commitments and Contingencies (Detail) (USD $)	Mar. 31, 2015
Commitments And Contingencies [Line Items]
Total	$1,876,000
2015	540,000
2016	334,000
2017	334,000
2018	334,000
2019	334,000
Thereafter	0
Manufacturing [Member]
Commitments And Contingencies [Line Items]
Total	68,000
2015	68,000
Thereafter	0
Clinical Research and Trial Obligations [Member]
Commitments And Contingencies [Line Items]
Total	388,000
2015	388,000
Thereafter	0
Sponsored Research Agreement with Related Party [Member]
Commitments And Contingencies [Line Items]
Total	298,000
2015	18,000
2016	70,000
2017	70,000
2018	70,000
2019	70,000
Thereafter	0
Management Fee [Member]
Commitments And Contingencies [Line Items]
Total	1,122,000
2015	66,000
2016	264,000
2017	264,000
2018	264,000
2019	264,000
Thereafter	$0

Commitments_and_Contingencies_2

Commitments and Contingencies - Additional Information (Detail) (USD $)	1 Months Ended		9 Months Ended
	Jan. 31, 2014	Jan. 31, 2013	Mar. 31, 2015
Commitments And Contingencies [Line Items]
Total commitment			$1,876,000
Amount paid by supplier	22,000	22,000
Manufacturing [Member]
Commitments And Contingencies [Line Items]
Total commitment			68,000
Sponsored Research Agreement with Related Party [Member]
Commitments And Contingencies [Line Items]
Total commitment			298,000
Sponsored Research Agreement termination notice period			30 days
Redox SYS System [Member] | Manufacturing [Member]
Commitments And Contingencies [Line Items]
Total commitment			68,000
Redox SYS System [Member] | Clinical Research Obligations [Member]
Commitments And Contingencies [Line Items]
Remaining contract commitments related to trial expense			199,000
Zertane Drug [Member] | Clinical Research Obligations [Member]
Commitments And Contingencies [Line Items]
Commitment remain under terms of clinical research agreement			$189,000

Common_Stock_Additional_Inform

Common Stock - Additional Information (Detail) (USD $)	9 Months Ended	1 Months Ended
	Mar. 31, 2015	Aug. 31, 2013	Jun. 30, 2014
Components Of Common Stock [Line Items]
Common Stock, shares authorized	120,000,000		120,000,000
Common Stock, par value	$0.00		$0.00
Preferred Stock, shares authorized	20,000,000		20,000,000
Preferred Stock, par value	$0.00		$0.00
Warrants to purchase common stock, Value	$313,000
Private Placement [Member]
Components Of Common Stock [Line Items]
Shares issued		4,652,500
Price per share		$1
Gross proceeds from issuance		4,653,000
Net proceeds from issuance		3,980,000
Warrants to purchase		465,250
Warrants to purchase common stock, Value		$313,000

Equity_Instruments_Additional_

Equity Instruments - Additional Information (Detail) (USD $)	9 Months Ended
Share data in Millions, unless otherwise specified	Mar. 31, 2015
	Stock_Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock option plan	2
Shares of common stock reserved for issuance	10
Warrants to purchase common stock, Value	$313,000
Luoxis Diagnostics [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock reserved for issuance	5
Vyrix Pharmaceuticals [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock reserved for issuance	5

Equity_Instruments_Luoxis_Stoc

Equity Instruments - Luoxis Stock Option Activity (Detail) (Luoxis Diagnostics [Member], USD $)	6 Months Ended	9 Months Ended
	Jun. 30, 2014	Mar. 31, 2015
Luoxis Diagnostics [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Beginning Balance		1,950,000
Number of Options, Granted		885,000
Number of Options, Exercised		0
Number of Options, Forfeited/Cancelled		0
Number of Options, Ending Balance	1,950,000	2,835,000
Number of Options, Exercisable		937,500
Number of Options, Available for grant		2,165,000
Weighted Average Exercise Price, Beginning Balance		$1
Weighted Average Exercise Price, Granted		$1.60
Weighted Average Exercise Price, Exercised		$0
Weighted Average Exercise Price, Forfeited/Cancelled		$0
Weighted Average Exercise Price, Ending Balance	$1	$1.19
Weighted average exercise price, Exercisable		$1
Weighted Average Remaining Contractual Life
Weighted Average Remaining Contractual Life, Outstanding	9 years 4 days	8 years 7 months 10 days
Weighted Average Remaining Contractual Life, Exercisable		8 years 3 months 4 days
Aggregate Fair Value, Beginning Balance		$1,374,000
Aggregate Fair Value, Ending Balance	1,374,000	2,541,000
Aggregate Fair Value, Exercisable		$687,000

Equity_Instruments_Vyrix_Stock

Equity Instruments - Vyrix Stock Option Activity (Detail) (Vyrix Pharmaceuticals [Member], USD $)	6 Months Ended	9 Months Ended
	Jun. 30, 2014	Mar. 31, 2015
Vyrix Pharmaceuticals [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Beginning Balance		950,000
Number of Options, Granted		0
Number of Options, Exercised		0
Number of Options, Forfeited/Cancelled		0
Number of Options, Ending Balance	950,000	950,000
Number of Options, Exercisable		475,000
Number of Options, Available for grant		4,050,000
Weighted Average Exercise Price, Beginning Balance		$0.70
Weighted Average Exercise Price, Granted		$0
Weighted Average Exercise Price, Exercised		$0
Weighted Average Exercise Price, Forfeited/Cancelled		$0
Weighted Average Exercise Price, Ending Balance	$0.70	$0.70
Weighted average exercise price, Exercisable		$0.70
Weighted Average Remaining Contractual Life, Outstanding	9 years 6 months 15 days	8 years 9 months 15 days
Weighted Average Remaining Contractual Life, Exercisable		8 years 9 months 15 days
Aggregate Fair Value, Beginning Balance		$417,000
Aggregate Fair Value, Ending Balance	417,000	417,000
Aggregate Fair Value, Exercisable		$208,000

Equity_Instruments_Summary_of_

Equity Instruments - Summary of Stock-Based Compensation Expense (Detail) (USD $)	3 Months Ended		9 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	$272,000	$84,000	$750,000	$385,000
Luoxis Diagnostics [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized expense at March 31, 2015	1,129,000
Weighted average remaining years to vest	2 years 2 months 23 days
Vyrix Pharmaceuticals [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized expense at March 31, 2015	194,000
Weighted average remaining years to vest	1 year 9 months 15 days
Research and Development Expenses [Member] | Stock Options [Member] | Luoxis Diagnostics [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	107,000	52,000	297,000	155,000
Research and Development Expenses [Member] | Stock Options [Member] | Vyrix Pharmaceuticals [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	8,000	29,000	26,000	29,000
General and Administrative Expenses [Member] | Stock Options [Member] | Luoxis Diagnostics [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	138,000	58,000	371,000	116,000
General and Administrative Expenses [Member] | Stock Options [Member] | Vyrix Pharmaceuticals [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	$19,000	($55,000)	$56,000	$85,000

Equity_Instruments_Warrants_Is

Equity Instruments - Warrants Issued in Conjunction with its Senior Convertible Debentures (Detail) (USD $)	9 Months Ended	12 Months Ended
	Mar. 31, 2015	Jun. 30, 2014
Number of Warrants Outstanding
Number of Warrants Outstanding, Beginning Balance	465,250
Number of Warrants Outstanding, Ending Balance	465,250	465,250
Warrants, Weighted Average Exercise Price
Weighted Average Exercise Price, Outstanding Beginning Balance	$1
Weighted Average Exercise Price, Outstanding Ending Balance	$1	$1
Weighted Average Remaining Contractual Life
Weighted Average Remaining Contractual Life, Warrants Outstanding	3 years 2 months 1 day	3 years 11 months 1 day
Registered Direct Placements [Member]
Number of Warrants Outstanding
Number of Warrants, Exercised	0

Related_Party_Transactions_Add

Related Party Transactions - Additional Information (Detail) (Ampio [Member], USD $)	1 Months Ended		9 Months Ended	1 Months Ended
	Dec. 31, 2013	Jun. 30, 2013	Mar. 31, 2015	Mar. 31, 2014	Nov. 30, 2013
Related Party Transaction [Line Items]
Common stock, shares purchased					20,000,000
Common stock purchase price, per share					$0.00
Sale of share under agreement	20,000,000
Scenario, Plan [Member] | Second Installment [Member]
Related Party Transaction [Line Items]
Equipment lease payments net		$615,000
Scenario, Plan [Member] | Second Installment [Member] | After Amendment [Member]
Related Party Transaction [Line Items]
Monthly equipment lease payments		6,000
Scenario, Plan [Member] | First Installment [Member]
Related Party Transaction [Line Items]
Contract term			60 months 15 days
Lease expiration date			Mar-19
Ampio Loan Agreement [Member]
Related Party Transaction [Line Items]
Total amount agreed on loan agreement				12,000,000	12,000,000
Term of loan agreement				1 year	1 year
Amount advances on loan agreement			8,000,000
Loan agreement interest rate minimum			2.17%
loan agreement interest rate maximum			3.32%

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Detail) (USD $)	9 Months Ended	0 Months Ended		2 Months Ended
	Mar. 31, 2015	Jun. 01, 2015	Apr. 16, 2015	19-May-15
Subsequent Event [Line Items]
Common stock shares outstanding	19,435,402
Reverse stock split, description	On June 1, 2015, the Rosewind shareholders will vote on a reverse stock split of the Companybs common stock at a ratio of one new share for every 12.174 shares outstanding.
Scenario, Forecast [Member]
Subsequent Event [Line Items]
Reverse stock split ratio		12.174
Subsequent Event [Member]
Subsequent Event [Line Items]
Cash consideration received				$4,000,000
Percent of common stock			81.50%
Common stock shares held by Ampio			57,970,000
Common stock shares outstanding			173,597,365
Subsequent Event [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Conversion of stock, shares converted			44,652,500
Number of outstanding shares resulting from conversion of stock			96,191,193
Subsequent Event [Member] | Promissory Note [Member]
Subsequent Event [Line Items]
Debt instrument principal amount			10,000,000
Subsequent Event [Member] | Luoxis Diagnostics [Member]
Subsequent Event [Line Items]
Cancellation of indebtedness amount			8,000,000
Subsequent Event [Member] | Vyrix Pharmaceuticals [Member]
Subsequent Event [Line Items]
Cancellation of indebtedness amount			4,000,000